Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.62 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.61 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.61 |
| ▸ | IKZF3 | Q9UKT9 | 5/20 | 0.58 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.58 |
| ▸ | BRD4 | O60885 | 2/20 | 0.58 |
| ▸ | TNF | P01375 | 1/20 | 0.58 |
| ▸ | IL1B | P01584 | 1/20 | 0.58 |
| ▸ | GSPT1 | P15170 | 3/20 | 0.48 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.47 |
| ▸ | MAP1LC3B | Q9GZQ8 | 3/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25565719 | 0.90 | CRBN (0.59) | CRBNIKZF1CSNK1A1IKZF3DDB1 | |
| SCHEMBL20242436 | 0.88 | CRBN (0.67) | CRBNIKZF1CSNK1A1IKZF3DDB1 | |
| SCHEMBL30080346 | 0.86 | CRBN (0.59) | CRBNIKZF1CSNK1A1IKZF3DDB1 | |
| SCHEMBL26317632 | 0.86 | CRBN (0.59) | CRBNIKZF1CSNK1A1IKZF3DDB1 | |
| SCHEMBL26323795 | 0.85 | CRBN (0.59) | CRBNIKZF1CSNK1A1IKZF3DDB1 | |
| SCHEMBL30080490 | 0.85 | CRBN (0.59) | CRBNIKZF1CSNK1A1IKZF3DDB1 | |
| SCHEMBL26317635 | 0.85 | CRBN (0.59) | CRBNIKZF1CSNK1A1IKZF3DDB1 | |
| SCHEMBL30080325 | 0.85 | CRBN (0.59) | CRBNIKZF1CSNK1A1IKZF3DDB1 | |
| SCHEMBL29225998 | 0.85 | CRBN (0.56) | CRBNIKZF1CSNK1A1IKZF3DDB1 | |
| SCHEMBL25034756 | 0.85 | CRBN (0.65) | CRBNIKZF1CSNK1A1IKZF3DDB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158157-A1 | POTENT AND SELECTIVE DEGRADERS OF ALK | ALK, ERBB2, PDGFRB | CRBN 500/4885IKZF1 738/4885CSNK1A1 861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.